Given the significant upregulation of CD11c and xCT in the HCC microenvironment after RFA and the potential immunosuppressive effect of SLC7A11/xCT in DCs, we speculated that RFA combined with targeting SLC7A11/xCT in DC would be a potential combination therapy strategy. This evidence concerns the gene ITGAX and hepatocellular carcinoma.